Friends of Leronlimab

Friends of Leronlimab
An Emerging Therapeutic Drug for mTNBC, HIV

☰

Recent News From CytoDyn


View	CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
View	CytoDyn Releases ESMO Breast Cancer Meeting Poster
View	CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
View	CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
View	CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
View	March 2025 Letter to Shareholders
View	CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
View	CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
View	December 2024 Letter to Shareholders
View	CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology

This is a private website & not associated with CYDY, Leronlimab, Vyrologix, CytoDyn or cytodyn.com All names, images & website links are the property of their respective owners.

This website is not giving any medical advice.
Do your own research.
Talk to your doctors.


Home	Menu


Privacy	Term of Service